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ongoing VB12 treatment. ConClusions: PPI and metformin use did not appear as 
determinants of VB12 status in GAU patients whereas calcium supplements seem 
promoting better VB12 status. Whether calcium has counteracting effect on PPIs and 
metformin should be further examined using adjusted-analyses in a larger sample.
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objeCtives: Adverse drug events (ADE) in the elderly are important sequelae of 
drug treatment playing a role in non-adherence and increased hospitalizations 
and emergency visits. This study sought to describe the rate of ADEs in an elderly 
population and to compare the characteristics of those who experienced ADEs to 
those who did not. Methods: This study was a retrospective cross-sectional analy-
sis that used a 10% random sample of the IMS LifeLink Health Plans commercial 
claims data during the period January 1,2001 through December 31, 2009. Subjects 
had to be at least 65 years of age and have had at least one year of continuous 
medical coverage. ADEs were defined based on previously published schema using 
ICD-9-CM codes that mention drug therapy or “due to drug” or “drug induced”. 
ADEs occurring in hospitalizations, emergency department visits, and outpatient 
physician visits are reported. Demographics, comorbidity, and health resource 
use were compared between persons with one or more ADEs compared to those 
without an ADE. Results: 402,078 persons were eligible with 2.1% having at least 
one ADE. The ADE exposed group was older (77.5 vs 74.9, p< 0.001), included more 
females (59.4% vs 54.5%, p< 0.001), had higher CCI scores (2.27 vs 1.53, p< 0.001and 
incurred nearly three times the average health care cost per person ($9,386 vs $2,962, 
p< 0.001). The most common ADEs experienced were mental disorders (0.30%) and 
dermatitis (0.24%) with anticoagulants (0.15%) and chemotherapy (0.13%) being 
the most prevalent associated drug groups. Nearly half (48.8%) of ADEs occurred in 
ED departments. ConClusions: Approximately 2% of persons age 65 and older 
experienced at least one ADE. ADEs frequently required ED care underscoring the 
severity of many ADEs and the need to develop interventions that can reduce ADE 
occurences in the elderly.
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objeCtives: Previous meta-analysis on adults confirmed the superiority of sequen-
tial therapy (ST) over standard triple drug therapy (STT) for Helicobacter pylori eradi-
cation. The evidence of demonstrating the efficacy of using ST is still lacking. The 
aim of this study was to conduct a systemic review and meta-analysis comparing 
the efficacy of ST versus STT for the treatment of Helicobacter pyloriinfection in 
children. Methods: We used the keywords such as “Helicobacter pylori”, “H. pylori”, 
“infection”,“sequential therapy”, “triple drug therapy” “children” and searched 
Cochrane library, PubMed and Google Scholar for all the relevant randomized con-
trolled trials (RCTs), comparing the efficacy of two treatments (ST: proton pump 
inhibitor (PPI) + 1 antibiotic for 5 days followed by PPI + 2 antibiotics for another 5 
days; STT: PPI + 2 antibiotics for 7-10 days). The eradication rates were abstracted 
from included RCTs and Review Manager was used to estimate the pooled risk 
ratio (RR). Results: Five full text studies were included in the meta-analysis. They 
were published from 2005 to 2013. Three out of the five studies were of good quality 
(Jadad score ≥ 3).The superiority of ST over STT on the effect of Helicobacter pylori 
eradication was demonstrated, RR 1.24 (95 % CI 1.14, 1.36). No heterogeneity (I2 = 0) 
and publication bias (funnel plot was symmetrical). In the subgroup analyses, ST 
remained superior to STT regardless of the length of the STT (7 days or 10 days) (RR 
1.24, RR 1.21) as well as the type of antibiotics used as a part of ST (metronidazole 
or tinidazole) (RR 1.24, RR 1.26). ConClusions: The study indicated sequential 
therapy is superior to standard triple drug therapy for the eradication of Helicobacter 
pylori infection in children. More large RCTs are warranted to further confirm the 
efficacy due to the limited number of published studies.
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objeCtives: To characterize the temporal course of psychoactive drug utilization 
in a cohort of newly diagnosed autistic individuals. Methods: A cohort was built 
using the provincial public health care insurance program (RAMQ) databases. Newly 
diagnosed subjects with ASD were selected (≥ 2 diagnoses (separate dates) with 
ICD-9 codes: 299.X, excluding 299.2) between January 1998 and December 2010. 
Cohort entry was the date of first diagnosis confirmed by the absence of ASD diag-
nosis in previous 5 years. Participants aged ≥ 26 years or those not covered by the 
RAMQ drug plan in the year preceding cohort entry were excluded. Demographic 
and clinical patient characteristics were assessed at cohort entry. Drug use profiles 
(anticonvulsants, antipsychotics, antidepressants, anxiolytics, ADHD drugs) were 
evaluated for 5 years of follow-up. Impact of age groups on drug use profiles and 
variations over time were analyzed using generalized estimating equations (GEE) 
methods. Results: A cohort of 2,989 subjects was identified (male: 80.2%; median 
age: 6 years). Prior to ASD diagnosis, 35.8% received at least 1 psychoactive drug. At 
1-year of follow-up, 44.9% of participants were receiving at least 1 psychoactive med-
objeCtives: Limited evidence exists on the risk of falls/fractures with use of 
anticholinergic medications in the elderly. This study examined the risk of falls/
fractures associated with anticholinergic medication use. Methods: A nested case-
control design was conducted using regional Medicare Advantage Plan database. The 
base population included individuals aged > 65 years, who survived during the entire 
study period (2009-2010), had at least one institutional and one outpatient claim in 
first 6 months (January-June 2009) and no event of falls/fractures during the first 6 
months (Base Period). Cases were identified as patients who experienced incident 
diagnosis of falls/fractures following the base period. For each case, 4 age and sex-
matched controls were selected using incidence density sampling (incidence den-
sity 1:4). The primary outcome was an event of incident falls/hip fracture, between 
July 1, 2009 and December 31, 2010. The primary exposure was prescription of any 
anticholinergic medication 30 days preceding the event date. Anticholinergic expo-
sure was defined based on the Anticholinergic Drug Scale (ADS). Conditional logistic 
regression model stratified on matched case-control sets was used, with exposure 
to anticholinergic levels 1, 2 or 3 as the independent variable, falls/fractures as 
the outcome variable and other covariates associated with the outcome. Results: 
The study sample consisted of 449 cases diagnosed with falls/fractures and 1,796 
controls. After adjusting for other covariates, anticholinergic use was not associ-
ated with a statistically significant risk of falls/fractures (Relative Risk, RR 1.03; 
95% CI, 0.82-1.31) compared to no use. The study findings remained consistent 
when high-level anticholinergic drugs (level 2/3) were considered (RR 1.19; 0.85-
1.65). ConClusions: Use of anticholinergic medications was not associated with 
a higher risk of falls/fractures compared to no use, among patients with no history 
of falls/fractures. Future studies are needed to address the role of dose and con-
comitant use of anticholinergics to evaluate falls risk in the elderly.
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objeCtives: Anticholinergic medications are frequently prescribed in the elderly, 
and have been associated with potential central and peripheral adverse events. 
The current study examined the risk of all-cause hospitalization associated with 
anticholinergic use in the elderly. Methods: The study used a case-control design 
nested within a cohort of elderly individuals enrolled in a regional Medicare 
Advantage Prescription Drug Plan. The base population consisted of individuals 
aged > 65 years, who survived during the entire study period, had at least one 
institutional and one outpatient claim in first 6 months (January-June 2009) and 
no event of hospitalization during the first 6 months (Base Period). Cases for the 
study experienced incident inpatient hospitalization anytime following the base 
period. For each case, 4 age- and sex-matched controls were selected using inci-
dence density sampling (incidence density 1:4). The primary outcome measure was 
all-cause inpatient hospitalization. Prescription of any anticholinergic medication 
30 days before the hospitalization date formed the primary exposure, and was 
defined using the Anticholinergic Drug Scale (ADS). Conditional logistic regression 
stratified on matched case-control sets was used to model the hospitalization risk, 
after controlling for additional risk factors predictive of the outcome. Results: 
There were 295 cases that experienced incident hospitalization, and 1,180 age and 
sex-matched controls. After controlling for other covariates, use of anticholinergic 
medications was not associated with a significantly higher risk of hospitalization 
(Relative Risk, RR 0.85; 95% CI, 0.62-1.17) compared to no use. The findings remained 
unchanged after considering higher level (Level 2/3) anticholinergic use (RR 0.97; 
0.61-1.54). ConClusions: The study found that anticholinergic medication use 
was not associated with a significantly higher risk of hospitalization compared to 
no use, among the elderly with no history of hospitalization. Future studies with 
diverse samples are required to address the role of dose and concomitant use of 
anticholinergic agents in the elderly.
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bACkgRound: Use of proton pump inhibitors (PPIs) and metformin have emerged 
as potential risk factors of vitamin B12 (VB12) deficiency. Conversely, calcium sup-
plements were shown to counteract the detrimental effect of metformin on VB12 
absorption. These drugs are commonly prescribed to frail older adults in whom, 
VB12 deficiency is prevalent and has serious consequences. objeCtives: To exam-
ine proportions of PPI, metformin, and calcium supplement users according to vita-
min B12 status in frail older adults upon their admission to a Geriatric Assessment 
Unit (GAU). Methods: This cross-sectional study was based on 172 medical chart 
reviews of patients discharged from the GAU between 2008 and 2012. VB12 status at 
admission was categorized as follows: ongoing treatment for VB12 deficiency, low 
(< 148pmol/L), low-normal (148-221pmol/L), and normal (> 221pmol/L) serum VB12 
concentration. Use of PPIs, metformin and calcium supplements was determined 
from the pharmacist report. Proportions of PPI, metformin, and calcium supplement 
users were compared between VB12 status categories using χ 42statistics. Results: 
Most patients were women (67%), ≥ 75 years old (78%), and community-living (90%). 
Serum VB12 concentration was low and low-normal in 19% and 25% of patients, 
respectively; 19% had ongoing VB12 treatment. Prevalence of PPI and metformin 
users was 47% and 17%, respectively; these proportions did not vary significantly 
according to VB12 status. The use of calcium supplements was also prevalent (56%). 
Interestingly, proportions of calcium supplement users was found to vary signifi-
cantly between categories of VB12 status (P< 0.001), being of 21%, 35% and 62% in 
those with low, low-normal and normal status, respectively, and of 54% in those 
